KOPRAN
|
The Current P/E Ratio of KOPRAN is 38.89.
| Share Price | ₹133.2 | Feb 18,2026 |
| Market Cap | ₹643.4 Cr | |
| Earnings-TTM | ₹16.5 Cr | TTM-Consolidated Results |
| Price/Earnings | 38.89x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of KOPRAN
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹643.4 Cr] as on Feb 18,2026
(/) Earnings [ ₹16.5 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 38.89x ]
Thus, for KOPRAN , the investors are currently willing to pay 38.89 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of KOPRAN !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of KOPRAN over the last five years.
Historical PE (Price/Earnings) ratio chart of KOPRAN
PE Ratio Performance Analysis for KOPRAN
- KOPRAN 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 19.11x.
- KOPRAN 's operated at median p/e ratio of 21.93x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, KOPRAN 's p/e ratio peaked in Mar2024 at 24.45x.
- KOPRAN 's p/e ratio hit its five-year low in Mar2021 of 7.37x.
How does KOPRAN 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| KOPRAN | 16.55 | 38.89 | 643.4 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 11,001.40 | 37.61 | 413,717.0 |
| DIVIS LABORATORIES LTD | 2,479.00 | 67.30 | 166,830.0 |
| CIPLA LTD | 4,544.70 | 23.98 | 108,978.0 |
| TORRENT PHARMACEUTICALS LTD | 2,272.00 | 62.71 | 142,479.0 |
| DR REDDYS LABORATORIES LTD | 5,508.70 | 19.41 | 106,905.0 |
| MANKIND PHARMA LTD | 1,796.65 | 47.68 | 85,665.3 |
| ZYDUS LIFESCIENCES LTD | 4,933.90 | 18.56 | 91,572.3 |
| LUPIN LTD | 4,669.18 | 21.79 | 101,749.0 |
| AUROBINDO PHARMA LTD | 3,513.20 | 19.17 | 67,358.5 |
| ABBOTT INDIA LTD | 1,524.13 | 36.90 | 56,239.7 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs KOPRAN 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 18.56x |
| Max industry PE | 67.30x |
| Median industry PE | 36.90x |
| Average industry PE | 35.82x |
You may also like the below Video Courses